Team 5 – Laboratory original articles


Figure 1 MUC chimioR couleur 10/02/14

“Mucins and chemoresistance
of epithelial cancer cells”

(Jonckheere et al, 2014)

équipe mucines, différenciation cancérogenèse épithéliales
You are here: Home > Mucine, epithelial differentiation and carcinogenesis > LABORATORY ORIGINAL ARTICLES



2018 | 2017 | 2016 | 2015 | 2014 | 2013


Jonckheere N, Van Seuningen I. Analysis of TCGA and cancer cell lines encyclopedia public databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas. En révision.


Lahdaoui F, Messager M, Vincent A, Hec F, Gandon A, Warlaumont M, Renaud F, Leteurtre E, Piessen G, Jonckheere N, Mariette C, Van Seuningen I. Depletion of MUC5B mucin in gastrointestinal cancer cells alters their tumorigenic properties: Implication of the Wnt/β-catenin pathway. 2017 Biochem J. 2017 Nov 1;474(22):3733-3746.

Gaudelot K, Gibier J-B, Pottier N, Hémon B, Van Seuningen I, Glowacki F, Leroy X, Cauffiez C, Gnemmi V, Aubert S, Perrais M. Anti-miR-21 strategy promotes chemosensitivity and decreases expression of multi-drug resistant genes in renal carcinoma. Tumor Biol, 2017 Jul;39(7):1010428317707372. doi: 10.1177/1010428317707372.

Coppin L, Vincent A, Frénois F, Duchene B, Lahdaoui F, Stechly L, Renaud F, Villenet C, Van Seuningen I, Leteurtre E, Dion J, Grandjean C, Poirier F, Figeac M, Delacour D, Porchet N, Pigny P. Galectin-3 is a non-classic RNA binding protein that stabilizes the mucin MUC4 mRNA in the cytoplasm of cancer cells. Sci Rep. Mar 6;7:43927.

Gibier, J-B, Hémon B, Fanchon M, Gaudelot K, Pottier N, Ringot B, Van Seuningen I,  Glowacki F, Cauffiez C, Blum D, Copin M-C, Perrais M, Gnemmi V. Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: nephroprotector in early phase, but pro-fibrotic in late phase. Biochim Biophys Acta-Mol Basis Dis, 2017 Mar 31;1863(6):1336-1349.


Corvaisier M, Bauzone M, Corfiotti F, Renaud F, El Amrani M, Monté D, Truant S, Leteurtre E, Formstecher P, Van Seuningen I, Gespach C, Huet G. Regulation of cellular quiescence by YAP/TAZ and cyclin E1 in colon cancer cells: implication in chemoresistance and cancer relapse. Oncotarget, 2016 Aug 30;7(35):56699-56712.

Coppin L, Benomar K, Corfiotti F, et al. CA-125, but not galectin-3, complements CA 19-9 for discriminating ductal adenocarcinoma versus non-malignant pancreatic diseases. Pancreatology 2016; 16: 115-120.

Renaud F, Mariette C, Vincent A, Wacrenier A, Maunoury V, Leclerc J, Coppin L, Crépin M, Van Seuningen I, Leteurtre E, Buisine MP. The serrated neoplasia pathway of colorectal tumors: Identification of MUC5AC hypomethylation as an early marker of polyps with malignant potential. Int J Cancer. 2016 Mar 15;138(6):1472-81.


Vasseur R, Skrypek N, Duchêne B, Renaud F, Martínez-Maqueda D, Vincent A, Porchet N, Van Seuningen I, Jonckheere N. The mucin MUC4 is a transcriptional and post-transcriptional target of K-ras oncogene in pancreatic cancer. Implication of MAPK/AP-1, NF-κB and RalB signaling pathways. Biochim Biophys Acta-Gene Reg Mech. 2015 Dec;1849(12):1375-84.

Tréhoux S, Delpu Y, Renaud F, Leteurtre E, Torrisani J, Jonckheere N, Van Seuningen I. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta-Mol Cell Res, 2015 Jul 1853(10)2392-2403.

Skrypek N, Vasseur R, Vincent A, Duchêne B, Van Seuningen I, Jonckheere N. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget. 2015 May 10;6(13):10853-67.

Desurmont T, Skrypek N, Duhamel A, Jonckheere N, Millet G, Leteurtre E, Gosset P, Duchêne B, Ramdane N, Hebbar M, Van Seuningen I, Pruvot FR, Huet G, Truant S. CXCR2 and its ligand CXCL7 are correlated to shorter disease-free and overall survival in metastatic colorectal cancer. Cancer Sci, 2015 Mar;106(3):262-9.

Renaud F, Vincent A, Mariette C, Crépin M, Stechly L, Truant S, Copin MC, Porchet N, Leteurtre E, Van Seuningen I*, Buisine MP*. MUC5AC hypomethylation is a predictor of microsatellite instability independently of clinical factors associated with colorectal cancer. Int J Cancer. 2015 Jun 15;136(12):2811-21.

Lahdaoui F, Delpu Y, Vincent A, Renaud F, Messager M, Duchêne B, Leteurtre E, Mariette C, Torrisani J, Jonckheere N, Van Seuningen I. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene, 2015 Feb 5;34(6):780-8.

Vincent A, Kazmierczak C, Duchêne B, Jonckheere N, Leteurtre E, Van Seuningen I. Cryosectioning the intestinal crypt-villus axis: an ex vivo method to study the dynamic of epigenetic modifications from stem cells to differentiated cells. Stem Cell Res. 2015 Jan;14(1):105-13.

Tréhoux S, Duchêne B, Jonckheere N, Van Seuningen I. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways. Biochem Biophys Res Commun. 2015 Jan 16;456(3):757-62.


Gronnier C, Bruyère E, Jonckheere N, Perrais M, Leteurtre E, Piessen G, Mariette C, Van Seuningen I. The MUC1 mucin regulates the tumorigenic properties of human esophageal adenocarcinomatous cells. Biochim Biophys Acta-Mol Cell Res. 2014 Nov;1843(11):2432-7.

Renaud F, Gnemmi V, Devos P, Aubert S, Crepin M, Coppin L, Ramdane N, Bouchindhomme B, Boidein M, Van Seuningen I, Do Cao C, Pattou F, Carnaille B, Pigny P, Wemeau JL, Leteurtre E. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse. Thyroid. 2014 Sep;24(9):1375-84.

Vincent A, Hong, S-M, Hu C, Omura N, Young A, Kim H, Yu J, Knight S, Ayars M, Griffith M, Van Seuningen I, Maitra A, Goggins M. Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget, 2014 May 15;5(9):2575-87.

Gnemmi V, Bouillez A, Gaudelot K, Hémon B, Ringot B, Pottier N, Glowacki F, Villers A, Cauffiez C, Van Seuningen I, Bernard D, Leroy X, Aubert S, Perrais M. MUC1 drives epithelial-mesenchymal transition in renal carcinoma through Wnt/b-catenin pathway and direct interaction with SNAIL promoter. Cancer Lett, 2014, May1;346(2): 225-36.

Perrais M, Rousseaux C, Ducourouble MP, Courcol R, Vincent P, Jonckheere N, Van Seuningen I. Helicobacter pylori urease and flagellin alter mucin gene expression in human gastric cancer cells. Gastric Cancer, 2014 Apr;17(2):235-46.

Bouillez A, Gnemmi V, Hémon B, Gaudelot K, Ringot B, Butruille C, Pottier N, Glowacki F, Cauffiez C, Hamdane M, Sergeant N, Van Seuningen I, Leroy X, Aubert S, Perrais M. MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. Oncotarget, 2014 Feb15;5(3): 754-63.

Touil* Y, Igoudjil* W, Corvaisier M, Dessein AF, Vandomme J, Monté D, Stechly L, Skrypek N, Langlois C, Grard G, Millet G, Leteurtre E, Dumont P, Truant S, Pruvot FR, Hebbar M, Fan Fan, Ellis LM, Formstecher P, Van Seuningen I, Gespach** C, Polakowska** R, Huet** G. Colon cancer cells escape 5FU chemotherapy and cell death by entering in stemness and a quiescent state associated with c-Yes/YAP axis. Clin Cancer Res, 2014 Feb 15; 20(4)837-46.


Gronnier C*, Bruyère E*, Piessen G, Briez E, Bot J, Buob D, Leteurtre E, Van Seuningen I**, Mariette C**. Operatively induced chronic reflux in rats: A suitable model for studying esophageal carcinogenesis? Surgery, 2013 Nov;154(5):955-67.

Skrypek N, Duchene B, Hebbar M, Leteurtre E, Van Seuningen I, Jonckheere N. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the concentrative nucleoside transporter family. Oncogene, 2013 Mar 28;32(13):1714-1723.

Van der Hauwaert C, Savary G, Gnemmi V, Glowacki F, Pottier N, Bouillez A, Maboudou P, Zini L, Leroy X, Cauffiez C, Perrais M, Aubert S. Isolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labeling. PLoS One. 2013 Jun 14;8(6):e66750.